earnings
confidence high
sentiment positive
materiality 0.75
Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M
HALOZYME THERAPEUTICS, INC.
2022-Q2 EPS reported
$0.58
revenue$269,644,000
- GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).
- FY22 guidance raised: total revenue $655-685M (prior $530-560M); non-GAAP EPS $2.10-2.25.
- Antares Pharma acquisition closed May 2022; expected to add $115-125M revenue in FY22.
- Operating income $34.1M vs $93.0M in Q2 2021, reflecting Antares-related transaction costs.
- Cash and marketable securities $209.4M on June 30, 2022, down from $740.9M at Dec 31, 2021.